Intellia Therapeutics, Inc. (NTLA) Lifted to “Hold” at ValuEngine
ValuEngine upgraded shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) from a sell rating to a hold rating in a research note published on Friday.
Other research analysts have also issued reports about the company. Jefferies Group LLC reaffirmed a buy rating and set a $36.00 target price on shares of Intellia Therapeutics in a research report on Thursday, June 22nd. Credit Suisse Group set a $24.00 target price on Intellia Therapeutics and gave the company a buy rating in a research report on Saturday, June 3rd. Chardan Capital reaffirmed a buy rating and set a $20.00 target price (up from $19.00) on shares of Intellia Therapeutics in a research report on Wednesday, August 2nd. TheStreet raised Intellia Therapeutics from a d+ rating to a c- rating in a research report on Thursday, July 6th. Finally, Cann reaffirmed a hold rating on shares of Intellia Therapeutics in a research report on Tuesday, August 1st. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $25.43.
Shares of Intellia Therapeutics (NASDAQ:NTLA) opened at 23.91 on Friday. Intellia Therapeutics has a 12-month low of $10.83 and a 12-month high of $26.70. The company has a 50-day moving average price of $22.21 and a 200 day moving average price of $22.21. The company’s market capitalization is $863.44 million.
Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.03). Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The business had revenue of $5.90 million for the quarter, compared to analyst estimates of $5.83 million. The firm’s quarterly revenue was up 40.5% on a year-over-year basis. On average, equities analysts anticipate that Intellia Therapeutics will post ($1.78) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/09/26/intellia-therapeutics-inc-ntla-lifted-to-hold-at-valuengine.html.
In other news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total value of $2,436,000.00. The sale was disclosed in a document filed with the SEC, which is available through this link. 12.80% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. acquired a new stake in Intellia Therapeutics during the second quarter worth about $583,000. Neuberger Berman Group LLC grew its holdings in Intellia Therapeutics by 14.9% during the second quarter. Neuberger Berman Group LLC now owns 49,517 shares of the company’s stock worth $792,000 after acquiring an additional 6,431 shares during the period. Airain ltd acquired a new stake in Intellia Therapeutics during the first quarter worth about $381,000. M&T Bank Corp acquired a new stake in Intellia Therapeutics during the first quarter worth about $162,000. Finally, Bank of Montreal Can grew its holdings in Intellia Therapeutics by 1,031.7% during the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after acquiring an additional 7,222 shares during the period. 46.52% of the stock is currently owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.